瑞司美替罗 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "瑞司美替罗" in Chinese language version.

refsWebsite

Global rank Chinese rank

3web.archive.org

1^st place

1^st place

4^th place

5^th place

1semanticscholar.org

11^th place

332^nd place

2^nd place

23^rd place

38^th place

9^th place

low place

low place

1madrigalpharma.com

low place

low place

aasld.org

Harrison SA. A 52-Week Phase 3 Clinical Trial of Resmetirom in 180 Patients with Well-Compensated NASH Cirrhosis. AASLD: The Liver Meeting. [2023-05-15]. （原始内容存档于2023-05-27）.

doi.org

Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. November 2019, 394 (10213): 2012–2024. PMID 31727409. S2CID 207976212. doi:10.1016/S0140-6736(19)32517-6.

madrigalpharma.com

ir.madrigalpharma.com

Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis (新闻稿). Madrigal Pharmaceuticals. December 19, 2022 [2023-05-15]. （原始内容存档于2023-12-16）.

nih.gov

ncbi.nlm.nih.gov

Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. November 2019, 394 (10213): 2012–2024. PMID 31727409. S2CID 207976212. doi:10.1016/S0140-6736(19)32517-6.

semanticscholar.org

api.semanticscholar.org

Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. November 2019, 394 (10213): 2012–2024. PMID 31727409. S2CID 207976212. doi:10.1016/S0140-6736(19)32517-6.

web.archive.org

Non-Alcoholic Fatty Liver Disease (NAFLD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape. Yahoo! Finance. January 23, 2023 [2023-05-15]. （原始内容存档于2023-02-07）.
Harrison SA. A 52-Week Phase 3 Clinical Trial of Resmetirom in 180 Patients with Well-Compensated NASH Cirrhosis. AASLD: The Liver Meeting. [2023-05-15]. （原始内容存档于2023-05-27）.
Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis (新闻稿). Madrigal Pharmaceuticals. December 19, 2022 [2023-05-15]. （原始内容存档于2023-12-16）.

yahoo.com

finance.yahoo.com

Non-Alcoholic Fatty Liver Disease (NAFLD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape. Yahoo! Finance. January 23, 2023 [2023-05-15]. （原始内容存档于2023-02-07）.